RESEARCH AND DEVELOPMENT
研究與開(kāi)發(fā)
熱烈祝賀華奧泰生物在國(guó)際學(xué)術(shù)期刊Frontiers in Immunology發(fā)表了題為 “A Novel Bispecific Antibody Targeting PD-L1 and VEGF with Combined Anti-Tumor Activities”的學(xué)術(shù)論文，華奧泰CEO朱向陽(yáng)博士是該論文的通訊作者。
該論文充分論述了華奧泰自主研發(fā)的全球首個(gè)靶向PD-L1/VEGF的雙特異性融合蛋白HB0025卓越的CMC性能，顯著的體內(nèi)體外協(xié)同抗腫瘤活性和巨大的臨床潛力。此研究為HB0025的臨床開(kāi)發(fā)提供了扎實(shí)的理論支持。HB0025已被中美兩國(guó)監(jiān)管機(jī)構(gòu)批準(zhǔn)進(jìn)入臨床，目前正在開(kāi)展一項(xiàng)評(píng)估HB0025安全性、耐受性和初步療效的國(guó)際多中心臨床研究。
論文下載鏈接：https://doi.org/10.3389/fimmu.2021.778978
(A) HB0025 treatment compared with HB0023, HB002.1T, and HB0023+HB002.1T in NCG mice. (B) HB0025 treatment compared with bevacizumab, atezolizumab, and bevacizumab+atezolizumab in NCG mice. *p < 0.05, **p < 0.01, ***p < 0.001 compared with HB0025 6mg/kg.